Abstract: A method for selectively chemically reducing CO2 to form CO includes providing a catalyst, and contacting H2 and CO2 with the catalyst to chemically reduce CO2 to form CO. The catalyst includes a metal oxide having a chemical formula of FexCoyMn(1-x-y)Oz, in which 0.7?x?0.95, 0.01?y?0.25, and z is an oxidation coordination number.

Abstract: Package structures and methods for manufacturing the same are provided. The package structure includes a first bump structure formed over a first substrate. The first bump structure includes a first pillar layer formed over the first substrate and a first barrier layer formed over the first pillar layer. In addition, the first barrier layer has a first protruding portion laterally extending outside a first edge of the first pillar layer. The package structure further includes a second bump structure bonded to the first bump structure through a solder joint. In addition, the second bump structure includes a second pillar layer formed over a second substrate and a second barrier layer formed over the second pillar layer. The first protruding portion of the first barrier layer is spaced apart from the solder joint.

Abstract: A package structure includes a bonding substrate, an integrated circuit, and a heat sink metal. The integrated circuit includes an active region facing the bonding substrate. The heat sink metal is located between the bonding substrate and the active region of the integrated circuit. The heat sink metal is electrically insulated with the integrated circuit.

Abstract: Embodiments disclosed herein relate to using an implantation process and a melting anneal process performed on a nanosecond scale to achieve a high surface concentration (surface pile up) dopant profile and a retrograde dopant profile simultaneously. In an embodiment, a method includes forming a source/drain structure in an active area on a substrate, the source/drain structure including a first region comprising germanium, implanting a first dopant into the first region of the source/drain structure to form an amorphous region in at least the first region of the source/drain structure, implanting a second dopant into the amorphous region containing the first dopant, and heating the source/drain structure to liquidize and convert at least the amorphous region into a crystalline region, the crystalline region containing the first dopant and the second dopant.

Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.

Abstract: The present invention relates to a composition and methods of administering the composition, comprising Citronellol and its analogues and derivatives, to humans and other mammalian animals with peptic ulcers induced by alcohol consumption, H. pylori infection, stress and/or intake of nonsteroidal anti-inflammatory medications.

Abstract: MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.

Abstract: MG20 (CCNDBP1) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MG20 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MG20 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MG20 expression or activity, thereby treating cancer, in vivo.